Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Withdrawn 2Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 7Neoplasms 3Uveal Melanoma 2Carcinoma, Non-Small-Cell Lung 2Thyroid Carcinoma, Anaplastic 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Recurrence 1Neoplasm Metastasis 1Multiple Myeloma 1Gastrointestinal Stromal Tumors 1

Interventions

trametinib 2olaparib 1glembatumumab vedotin 1durvalumab 1cediranib 1Vorinostat 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1CTLA-4 Antigen 1CR011-vcMMAE 1Biopsy, Fine-Needle 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Uveal Melanoma × trametinib × Clear all
NCT05677373 2023-08-18

Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma

Alliance for Clinical Trials in Oncology

Phase 1/2 Withdrawn
Dermatologic

Uveal Melanoma

NCT01328106 2017-12-12

Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma

GlaxoSmithKline

Phase 2 Withdrawn
Dermatologic

Uveal Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡